Literature DB >> 34331177

Durable Viral Suppression Among People with HIV and Problem Substance Use in the Era of Universal Antiretroviral Treatment.

Margaret M Paschen-Wolff1, Aimee N C Campbell2, Susan Tross3, Tse-Hwei Choo4, Martina Pavlicova5, Sarah Braunstein6, Rachael Lazar6, Christine Borges7, Michael Castro7, Hayley Berg8, Graham Harriman6, Robert H Remien3, Don Des Jarlais8.   

Abstract

This study explored factors associated with durable viral suppression (DVS) among two groups of people living with HIV (PLWH) and problem substance use in the context of universal antiretroviral treatment initiation. Participants (N = 99) were recruited between 2014-2017 from public sexual health clinics [SHC] and a hospital detoxification unit [detox]). DVS (NYC HIV surveillance registry) was defined as two consecutive viral load tests ≤ 200 copies/mL, ≤ 90 days apart, with all other viral loads suppressed over 12 or 18 months. Detox participants were significantly older, with more unstable housing/employment, substance use severity, and longer-term HIV vs. SHC participants. Older age, opioid and stimulant use disorder were significantly associated with lower odds of DVS, while fulltime employment and stable housing were significantly associated with higher odds of DVS at 12-month follow-up. Patterns held at 18-month follow-up. Co-located substance use and HIV services, funding for supportive housing, and collaborative patient-provider relationships could improve DVS among populations with the syndemic of problem substance use, poverty, and long-term HIV.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adherence; Antiretroviral therapy; HIV/AIDS; Substance use; Viral load

Mesh:

Substances:

Year:  2021        PMID: 34331177      PMCID: PMC8800950          DOI: 10.1007/s10461-021-03392-9

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  38 in total

Review 1.  HIV treatment as prevention among injection drug users.

Authors:  Evan Wood; Michael John Milloy; Julio S G Montaner
Journal:  Curr Opin HIV AIDS       Date:  2012-03       Impact factor: 4.283

2.  HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response.

Authors:  Myron S Cohen; Charles Holmes; Nancy Padian; Megan Wolf; Gottfried Hirnschall; Ying-Ru Lo; Eric Goosby
Journal:  Health Aff (Millwood)       Date:  2012-07       Impact factor: 6.301

Review 3.  Oral substitution treatment of injecting opioid users for prevention of HIV infection.

Authors:  Linda Gowing; Michael F Farrell; Reinhard Bornemann; Lynn E Sullivan; Robert Ali
Journal:  Cochrane Database Syst Rev       Date:  2011-08-10

Review 4.  The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.

Authors:  Julio S G Montaner; Robert Hogg; Evan Wood; Thomas Kerr; Mark Tyndall; Adrian R Levy; P Richard Harrigan
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

5.  Cost-utility analysis of the housing and health intervention for homeless and unstably housed persons living with HIV.

Authors:  David R Holtgrave; Richard J Wolitski; Sherri L Pals; Angela Aidala; Daniel P Kidder; David Vos; Scott Royal; Nkemdiri Iruka; Kate Briddell; Ron Stall; Arturo Valdivia Bendixen
Journal:  AIDS Behav       Date:  2013-06

Review 6.  A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy.

Authors:  Kasey R Claborn; Ellen Meier; Mary Beth Miller; Thad R Leffingwell
Journal:  Psychol Health Med       Date:  2014-08-11       Impact factor: 2.423

7.  Timeliness of Human Immunodeficiency Virus Diagnosis and Antiretroviral Treatment Initiation in the Era of Universal Testing and Treatment.

Authors:  McKaylee M Robertson; Sarah L Braunstein; Donald R Hoover; Sheng Li; Denis Nash
Journal:  J Infect Dis       Date:  2019-07-19       Impact factor: 5.226

8.  HIV Treatment Knowledge in the Context of "Treatment as Prevention" (TasP).

Authors:  Margaret M Paschen-Wolff; Aimee N C Campbell; Susan Tross; Michael Castro; Hayley Berg; Sarah Braunstein; Christine Borges; Don Des Jarlais
Journal:  AIDS Behav       Date:  2020-04-04

9.  Short screening scales to monitor population prevalences and trends in non-specific psychological distress.

Authors:  R C Kessler; G Andrews; L J Colpe; E Hiripi; D K Mroczek; S L T Normand; E E Walters; A M Zaslavsky
Journal:  Psychol Med       Date:  2002-08       Impact factor: 7.723

10.  Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis - United States, 2013-2018.

Authors:  Norma S Harris; Anna Satcher Johnson; Ya-Lin A Huang; Dayle Kern; Paul Fulton; Dawn K Smith; Linda A Valleroy; H Irene Hall
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-12-06       Impact factor: 17.586

View more
  2 in total

1.  HIV-related drivers of sexual compulsivity and sexuality in sexual minority men who use methamphetamine.

Authors:  Hema R Kondur; Tae K Lee; Roger McIntosh; Hetta Gouse; Robert Paul; Christian Grov; Dietmar Fuchs; Walter Gómez; Samantha E Dilworth; Torsten B Neilands; Adam W Carrico
Journal:  J Neurovirol       Date:  2022-07-12       Impact factor: 3.739

2.  Advancing behavioral interventions for African American/Black and Latino persons living with HIV using a new conceptual model that integrates critical race theory, harm reduction, and self-determination theory: a qualitative exploratory study.

Authors:  Marya Gwadz; Sabrina R Cluesman; Robert Freeman; Linda M Collins; Caroline Dorsen; Robert L Hawkins; Charles M Cleland; Leo Wilton; Amanda S Ritchie; Karen Torbjornsen; Noelle R Leonard; Belkis Y Martinez; Elizabeth Silverman; Khadija Israel; Alexandra Kutnick
Journal:  Int J Equity Health       Date:  2022-07-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.